Table 2.
No. | Reference (Localisation) |
(EWGSOP) Criteria (Yes/No) | Definition of Sarcopenia | Body Composition Assessment (DXA/BIA) and Nutritional Status (BMI, MNA) |
Muscle Strength and Physical Performance Assessment | ||||
---|---|---|---|---|---|---|---|---|---|
Handgrip Strength | SPPB | Chair-Stand Time | Balance Test | Gait Speed | |||||
1. | Bauer et al., 2015 [24] (multicentre) |
YES (EWGSOP) | Sarcopenia was defined as “the age-related loss of muscle mass, strength, and function makes up a large component of physical frailty” | DXA/ BMI by BIA, MNA | Handgrip dynamometry | SPPB score | Chair-stand test score | Balance tests | 4-m walk |
2. | Bauer et al., 2020 [25] (multicentre) |
YES (EWGSOP) | Sarcopenia was defined as “low skeletal muscle mass index (SMI) combined with mild to moderate limitations in physical performance” | BMI, MNA-SF | nd | nd | nd | nd | nd |
3. | Björkman et al., 2020 [26] (Finland) |
YES (EWGSOP) | Sarcopenia was defined as “low muscle strength, low muscle quantity or quality, and low physical performance” | BIA, tetrapolar BIS device | Handgrip dynamometry | nd | Chair-stand test score | nd | 4-m walk |
4. | Bo et al., 2019 [27] (China) |
YES (EWGSOP) |
|
BIA, MNA | Handgrip dynamometry | nd | Chair stand test score | nd | 6-m walk |
5. | Hameed, 2018 [28] (Iraq) |
YES (EWGSOP) | “Sarcopenia was measured using hydraulic hand dynamometer, SPPB (balance, chair stand test, and gait speed)” | MNA | Handgrip dynamometry | SPPB score | Chair-stand test score | Balance tests | nd |
6. | Hill et al., 2019 [29] (multicentre) |
nd | “Sarcopenia was determined by Short Physical Performance Battery (SPPB; 0–12) scores between 4 and 9, and a low skeletal muscle mass index (SMI; skeletal muscle mass/BW × 100) ≤ 37% in men and ≤ 28% in women using bioelectric impedance analysis” | DXA, BIA/ BMI, MNA | nd | SPPB score | nd | nd | nd |
7. | Liberman et al., 2019 [30] (multicentre) |
YES (EWGSOP) | Sarcopenia was defined as “a muscle failure disease that is caused by adverse muscle changes that accumulate over life” | DXA, BMI | nd | SPPB score | nd | nd | nd |
8. | Rondanelli et al., 2016 [31] (Italy) |
YES (EWGSOP) | Sarcopenia was defined as “the age-related depletion of skeletal muscle mass and loss of strength” | DXA, BIA | Handgrip dynamometry | nd | Chair-stand test score | nd | nd |
9. | Rondanelli et al., 2020 [32] (Italy) |
YES (EWGSOP) | Sarcopenia was defined “according to European Working Group on Sarcopenia in Older People (EWGSOP) 2010 criteria in terms of the outcome of body composition by bioimpedance analysis [(skeletal muscle mass/body weight × 100) ≤ 37% in men and ≤28% in women], handgrip strength, and gait speed” | DXA, BIA | Handgrip dynamometry | SPPB score | Chair-stand test score | Balance tests | 4-m walk |
10. | Verlaan et al., 2018 [33] (multicentre) |
YES (EWGSOP) | Sarcopenia was defined as “the geriatric syndrome characterized by low muscle mass, strength, and function” | DXA/ BMI by BIA, MNA-SF | Handgrip dynamometry | SPPB score | Chair-stand test score | nd | 4-m walk |
nd—no data;; source: the authors’ own analysis, EWGSOP: European Working Group for Sarcopenia in Older People.